Compare · CNSY vs WST
CNSY vs WST
Side-by-side comparison of Cerenome Inc. (CNSY) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNSY and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $28.65B, about 4896.6x CNSY ($5.9M).
- WST has been more active in the news (7 items in the past 4 weeks vs 4 for CNSY).
- WST has more recent analyst coverage (20 ratings vs 0 for CNSY).
- Company
- Cerenome Inc.
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $5.9M
- $28.65B
- 1M return
- -
- +9.75%
- 1Y return
- -
- +54.32%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 7
- Recent ratings
- 0
- 20
Cerenome Inc.
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest CNSY
- Chief Business Officer Andrews Ronald Asbury was granted 92,858 stock options (SEC Form 4)
- Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
- Cerenome Appoints Director Ron Andrews as Chief Business Officer
- Cerenome Secures National In-Network Agreement with Aetna for CNSide®
Latest WST
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.
- West to Participate in Upcoming Investor Conference
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- SEC Form 8-K filed by West Pharmaceutical Services Inc.
- West Reports Third-Quarter 2026 Results
- SEC Form 8-K filed by West Pharmaceutical Services Inc.
- West Declares Quarterly Dividend
- West to Host Third-Quarter 2026 Conference Call
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- SEC Form 4 filed by Director Haugen Janet Brutschea